UBS Raises Kenvue Inc. (KVUE) Price Target to $19 After Strong Q4 Results

On February 18, UBS raised the firm’s price target on Kenvue Inc. (NYSE:KVUE) to $19 from $17 while maintaining a Neutral rating following fourth-quarter results that were better than expected. The same day, Canaccord Genuity increased its price target to $18 from $17 and kept a Hold rating, noting that Kenvue delivered a beat on both the top and bottom lines. Analysts highlighted that all three of the company’s business segments recorded year-over-year growth for the first time since the second quarter of 2023, supported in part by favorable foreign exchange tailwinds.

Also on February 18, Citigroup raised its price target on Kenvue Inc. (NYSE:KVUE) to $20 from $18 while maintaining a Neutral rating. The company reported fourth-quarter 2025 revenue of $3.78 billion, exceeding the consensus estimate of $3.69 billion. Chief Executive Officer Kirk Perry stated that the company ended 2025 with stronger top- and bottom-line performance driven by disciplined execution of strategic priorities and easier year-over-year comparisons. Management also noted its continued progress toward completing a value-creating combination with Kimberly‑Clark.

Kenvue Inc. (NYSE:KVUE) was founded in 2022 as a spin-off from Johnson & Johnson and is headquartered in Summit, New Jersey. The company operates as a major global consumer health firm. Its portfolio includes widely recognized brands such as Tylenol, Neutrogena, Band‑Aid, Listerine, and Aveeno.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.